Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2014

View Archived Issues

Potency of a novel NRTI against drug-resistant retroviruses

Phase III clinical data for DTaP5-IPV-Hib-HepB vaccine in infants

GW Pharmaceuticals provides new physician reports of Epidiolex

Capricor Therapeutics acquires rights to family of natriuretic peptides

DKFZ to evaluate Imaxio's pro-immunogenic technology in HPV vaccine

Johnson & Johnson reports on active third quarter 2014

NanoLogix configuring N-Assay Rapid diagnostic kits for viruses

Idera's IMO-9200 moves into phase I development

Compound derived from traditional Chinese medicine has antipsoriatic activity

Purdue Pharma patents novel Nav1.7 blockers for pain

New BUB1 inhibitors disclosed by Bayer Schering Pharma for cancer

Researchers at Aptose Biosciences patent new agents for cancer

Beta cell-specific insulin gene knockout model reveals pancreatic cell fate in diabetes

Actinobac Biomed receives second NIH grant to support development of Leukothera

Novel Nav1.7 blockers divulged by Genentech and Xenon Pharmaceuticals

Advaxis reports preliminary data from phase I/II trial of ADXS-HPV in anal cancer

ActoGeniX reports data from phase I study of AG-014

FDA approves two idiopathic pulmonary fibrosis drugs ahead of schedule

Hanmi Pharmaceuticals and Kinex Pharmaceuticals report data from phase I Oratecan study

Alexion submits NDA in Japan for asfotase alfa

Retrophin to divest non-core assets to Turing Pharmaceuticals

FDA clears Lyra Parainfluenza Assay for use

FDA issues refusal to file letter in response to Insys' NDA for dronabinol

FDA grants priority review for lenvatinib in thyroid cancer

Nivolumab and ipilimumab combination receives FDA orphan drug designation

Compstatin 40 given U.S. orphan drug status for paroxysmal nocturnal hemoglobinuria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...